Journal Publications

[41]Guo Y., Cao M., Li Z., Zhou H., Chen Z., Li Q. Discovery of a novel 2,4-thiazolidinedione derivative as dual inhibitor of beta-catenin/TCF4 interaction and tubulin polymerization in colon cancer cells. Arch Pharm (Weinheim), 2025, 358(3): e2400796.
[42]Hu X., Wu Y., Yao M., Chen Z., Li Q. The other side of the coin: protein deubiquitination by Ubiquitin-Specific Protease 1 in cancer progression and therapy. Future Med. Chem., 2025, 17(3): 329-345.
[43]Hu Y., Wang Y., Tan W., Zhao C., Li M., Xiang S., Liang X., Gao R., Zeng B., Chen Z., Hu L., Li Q. Design and Optimization of LOXL2 and sGC Dual-Target Regulators Targeting Extracellular Matrix Dysregulation and Vasodilation for the Treatment of Pulmonary Arterial Hypertension. J Med Chem, 2025.
[44]Le X., Chen Q., Cao S., Hu G., Li Q., Chen Z. Pan-Cdk inhibitor ZK304709 suppresses Cdc20 expression and potentiates the anticancer activity of apcin in HeLa cervical cancer cells. Acta. Pharm., 2025.
[45]Le X., Chen Q., Wen Q., Cao S., Zhang L., Hu L., Hu G., Li Q., Chen Z. Design, synthesis and optimization of Apcin analogues as Cdc20 inhibitors for triple-negative breast cancer therapy. Eur J Med Chem, 2025, 289: 117434.
[46]Tan W., Wang Y., Li M., Zhao C., Hu Y., Gao R., Chen Z., Hu L., Li Q. A novel pyridine-2-one AMPK inhibitor: Discovery, mechanism, and in vivo evaluation in a hypoxic pulmonary arterial hypertension rat model. Eur J Med Chem, 2025, 286: 117266.
[47]Wei J., Feng W., Chen Q., Li Q., Chen Z. Rational discovery of molecular glue degraders based on block chemistry. Drug Discov Today, 2025, 30(11): 104480.
[48]Wu Y., Hu X., Wang S., Ouyang H., Yao M., Chen Z., Li Q. Fragment-based discovery, dynamics simulation and pharmacological study of 2-amino-pyrimidine derivative as HIPK2 inhibitor. Chem. Biol. Interact., 2025, 421: 111771.
[49]Zhao R., Zhao C., Gao R., Cai Q., Li Q., Hu L. Exploration of small-molecule inhibitors targeting Hsp110 as novel therapeutics. Drug Discov Today, 2025, 30(1): 104287.
[50]Hu X., Wang S., Fu S., Zeng J., Wu Y., Gong L., Cao Y., Zhang Y., Han Y., Ouyang H., Xiong Y., He X., Cheng J., Zou S., Chen Z., Tao L., Meng J., Huang L., Yuan Q., Peng Z., Li Q. Discovery of XRF-1021, a 2,4-disubstituted-5-fluoropyrimidine derivative as a homeodomain-interacting protein kinase 2 inhibitor for the treatment of chronic kidney disease. Eur J Med Chem, 2026, 302(Pt 2): 118353.
[51]Yao M., Wu Y., Hu X., Feng C., Xu J., Chen Z., Li Q. Design, synthesis, and in vitro anti-renal fibrotic effects of imidazopyridazine-based homeodomain-interacting protein kinase 2 inhibitors. Bioorg Med Chem, 2026, 132: 118456.
[52]Li, Q., Xu, W. Novel anticancer targets and drug discovery in post genomic age. Curr. Med. Chem. Anticancer Agents 2005, 5(1): 53-63.
[53]Xu, W., Li, Q. Progress in the development of aminopeptidase N (APN/CD13) inhibitors. Curr. Med. Chem. Anticancer Agents 2005, 5(3): 281-301.
[54]Li, Q., Fang, H., Xu, W. Novel 3-galloylamido-N'-substituted-2,6 -piperidinedione-N-acetamide peptidomimetics as metalloproteinase inhibitors. Bioorg. Med. Chem. Lett. 2007, 17(10): 2935-2938.
[55]Li, Q., Al-Ayoubi, A., Guo, T., Zheng, H., Sarkar, A., Nguyen, T., Eblen, S.T., Grant, S., Kellogg, G.E., Zhang, S. Structure-activity relationship (SAR) studies of 3-(2-amino-ethyl)-5-(4-ethoxy-benzylidene)-thiazolidine-2,4-dione: development of potential substrate-specific ERK1/2 inhibitors. Bioorg. Med. Chem. Lett. 2009, 19(21): 6042-6046.
[56]Li, Q., Fang, H., Wang, X., Hu, L., Xu, W. Novel cyclic-imide peptidomimetics as aminopeptidase N inhibitors. Design, chemistry and activity evaluation. Part I. Eur. J. Med. Chem. 2009, 44(12): 4819-4825.
[57]Li, Q., Fang, H., Wang, X., Xu, W. Novel cyclic-imide peptidomimetics as aminopeptidase N inhibitors. Structure-based design, chemistry and activity evaluation. II. Eur. J. Med. Chem. 2010, 45(4): 1618-1626.
[58]Li, Q., Wu, J., Zheng, H., Liu, K., Guo, T.L., Liu, Y., Eblen, S.T., Grant, S., Zhang, S. Discovery of 3-(2-aminoethyl)-5-(3-phenyl-propylidene)-thiazolidine -2,4-dione as a dual inhibitor of the Raf/MEK/ERK and the PI3K/Akt signaling pathways. Bioorg. Med. Chem. Lett. 2010, 20(15): 4526-4530.
[59]Li, Q., Fang, H., Wang, X., Hu, G., Wang, Q., Xu, W. Novel potent 2,5-pyrrolidinedione peptidomimetics as aminopeptidase N inhibitors. Design, synthesis and activity evaluation. Bioorg. Med. Chem. Lett. 2012, 22(2): 850-853.
[60]Lv, M., Chen, Z., Hu, G., Li, Q. Therapeutic strategies of diabetic nephropathy: recent progress and future perspectives. Drug Discov. Today 2015, 20(3): 332-346.

total68 3/4

first previous next last Page

李乾斌